| EMV Capital portfolio company PDS Biotech advances cancer trial |
PDS Biotechnology Corporation (NASDAQ:PDSB), a US cancer immunotherapy firm backed by EMV Capital (AIM:EMVC), has begun site activations for its phase III trial of Versamune HPV in patients with head and neck cancers linked to HPV16. The trial, which will enrol around 350 patients, is supported by the US Food and Drug Administration Fast Track designation and includes interim data readouts. |
proactiveinvestors.co.uk |
2025-05-15 06:53:50 |
Czytaj oryginał (ang.) |
| PDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call Transcript |
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Frank Bedu-Addo - CEO Lars Boesgaard - CFO Kirk Shepard - Chief Medical Officer Mike Moyer - IR, LifeSci Advisors Conference Call Participants Mayank Mamtani - B. Riley Securities Joseph Pantginis - H.C. |
seekingalpha.com |
2025-05-14 16:57:01 |
Czytaj oryginał (ang.) |
| PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update |
VERSATILE-003 Phase 3 Site Initiations Underway Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J. |
globenewswire.com |
2025-05-14 11:30:00 |
Czytaj oryginał (ang.) |
| PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
PRINCETON, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that on May 5, 2025, PDS Biotech granted a nonstatutory stock option to purchase 5,000 shares of common stock to an employee in its clinical department as a material inducement to such employee's employment and in accordance with Nasdaq Listing Rule 5635(c)(4) and PDS Biotech's 2019 Inducement Plan, as amended, which was adopted on June 17, 2019, and provides for the granting of equity awards to new employees of PDS Biotech. |
globenewswire.com |
2025-05-09 20:05:00 |
Czytaj oryginał (ang.) |
| PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results |
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the quarter ended March 31, 2025, and provide a clinical programs update on Wednesday, May 14, 2025 at 8:00 a.m. |
globenewswire.com |
2025-05-07 12:00:00 |
Czytaj oryginał (ang.) |
| PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting |
PRINCETON, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that three abstracts on Versamune® HPV (PDS0101) have been accepted for presentation at the 2025 American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 30-June 3, 2025, in Chicago, Illinois. |
globenewswire.com |
2025-04-23 14:16:00 |
Czytaj oryginał (ang.) |
| PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting |
PRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that preclinical immune response data with a novel Infectimune® based flu vaccine will be featured in a symposium on universal influenza vaccines at the American Association of Immunologists' IMMUNOLOGY2025™ Annual Meeting, taking place May 3-7, 2025, in Honolulu, Hawaii. |
globenewswire.com |
2025-04-16 12:00:00 |
Czytaj oryginał (ang.) |
| PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 |
NCI presentation to highlight IL-12 fused antibody drug conjugate during poster presentation PRINCETON, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that an abstract submitted by the National Cancer Institute (“NCI”) reporting clinical data on PDS01ADC, the Company's IL-12 fused antibody drug conjugate, has been accepted for presentation at the American Association for Cancer Research (“AACR”) Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois. |
globenewswire.com |
2025-04-08 12:00:00 |
Czytaj oryginał (ang.) |
| PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call Transcript |
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Tom Johnson - LifeSci Advisors Frank Bedu-Addo - CEO Kirk Shepard - Chief Medical Officer Lars Boesgaard - CFO Conference Call Participants Joseph Pantginis - H.C. Wainwright Mayank Mamtani - B. |
seekingalpha.com |
2025-03-27 12:35:47 |
Czytaj oryginał (ang.) |
| PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update |
Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune ® HPV in HPV16-Positive Head and Neck Cancer |
globenewswire.com |
2025-03-27 09:30:00 |
Czytaj oryginał (ang.) |
| PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference |
PRINCETON, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, will present at the 2025 Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer Conference in New Orleans on Friday, March 28 – Saturday, March 29, 2025. |
globenewswire.com |
2025-03-25 10:00:00 |
Czytaj oryginał (ang.) |
| PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results |
PRINCETON, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the year ended December 31, 2024, and provide a clinical programs update on Thursday, March 27, 2025, at 8:00 a.m. |
globenewswire.com |
2025-03-18 10:00:00 |
Czytaj oryginał (ang.) |
| PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer |
Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune ® platform candidate targets MUC1-positive solid tumors U.S. Patent #12,201,685 covering methods of using combinations of the Versamune ® platform and various immunocytokines, including PDS01ADC recently issued PRINCETON, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (“IND”) application filed in January 2025 to evaluate a combination of Versamune® MUC1 (formerly PDS0103), its novel investigational MUC1-targeted immunotherapy candidate + PDS01ADC to treat MUC1-positive unresectable, metastatic colorectal carcinoma (“mCRC”) in patients who failed previous treatment. |
globenewswire.com |
2025-03-13 10:00:00 |
Czytaj oryginał (ang.) |
| PDS Biotech Leadership to Participate in March Conferences |
PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, will present at the Zacks SCR Life Sciences Virtual Investor Forum on Thursday, March 13, 2025, and the 2025 Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer Conference in New Orleans on Friday, March 28 – Saturday, March 29, 2025. |
globenewswire.com |
2025-03-11 10:00:00 |
Czytaj oryginał (ang.) |
| PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer |
First-ever HPV16-positive head and neck cancer Phase 3 clinical trial First-ever HPV16-positive head and neck cancer Phase 3 clinical trial |
globenewswire.com |
2025-03-07 10:45:00 |
Czytaj oryginał (ang.) |
| EMV Capital portfolio company PDS Biotechnology raises $11mln |
EMV Capital plc (AIM: EMVC) portfolio company PDS Biotechnology Corporation (Nasdaq: PDSB) has raised $11 million, through an equity funding. PDS, which is focussed on immunotherapies, sold around 7.33 million new shares in a direct offer, plus warrants which (if exercised) will bring in another $11 million. |
proactiveinvestors.co.uk |
2025-02-28 05:34:11 |
Czytaj oryginał (ang.) |
| PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules |
PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced it has entered into securities purchase agreements with new and existing healthcare focused institutional investors as well as participation from certain directors of the Company, for the purchase and sale of 7,330,121 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 7,330,121 shares of common stock in a registered direct offering priced at-the-market under Nasdaq rules (the "Offering") at a combined purchase price of $1.50 for the institutional investors and $1.66 for certain directors of the Company. |
globenewswire.com |
2025-02-27 10:00:00 |
Czytaj oryginał (ang.) |
| PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology |
Median Overall Survival (mOS) of 42.4 months in immune checkpoint inhibitor naïve patients; Historical published result is 7-12 months Continued survival in the cohort of HPV16-positive immune checkpoint inhibitor naïve patients - mOS not yet reached Median OS of 17 months in HPV16-positive immune checkpoint inhibitor resistant patients; Historically published result is 3-4 months Significant tumor shrinkage with confirmed objective response rate (ORR) of 75% in HPV16-positive immune checkpoint inhibitor naïve patients; Historically published result is 11-24% PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the publication of clinical results in the Journal of the American Medical Association (JAMA) Oncology. |
globenewswire.com |
2025-02-26 10:00:00 |
Czytaj oryginał (ang.) |
| PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research |
Data confirms Versamune ® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025 |
globenewswire.com |
2025-02-24 10:00:00 |
Czytaj oryginał (ang.) |
| PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025 |
PRINCETON, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will participate in a fireside chat at the B. |
globenewswire.com |
2025-02-20 10:00:00 |
Czytaj oryginał (ang.) |
| PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
PRINCETON, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that on December 3, 2024, PDS Biotech granted nonstatutory stock options to purchase 7,000 shares of common stock to an employee in the clinical department as a material inducement to employment with PDS Biotech and in accordance with Nasdaq Listing Rule 5635(c)(4) and PDS Biotech's 2019 Inducement Plan, as amended, which was adopted on June 17, 2019, and provides for the granting of equity awards to new employees of PDS Biotech. |
globenewswire.com |
2024-12-06 10:00:00 |
Czytaj oryginał (ang.) |
| PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET |
Discussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and initiation Discussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and initiation |
globenewswire.com |
2024-12-03 10:00:00 |
Czytaj oryginał (ang.) |
| Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround |
The heavy selling pressure might have exhausted for PDS Biotechnology (PDSB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2024-11-20 12:35:29 |
Czytaj oryginał (ang.) |
| PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript |
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Tom Johnson - LifeSci Advisors Frank Bedu-Addo - Chief Executive Officer Lars Boesgaard - Chief Financial Officer Kirk Shepard - Chief Medical Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Ali Rashidfarrokhi - B. Riley Robert LeBoyer - Noble Capital Markets Operator Good morning ladies and gentlemen and welcome to PDS Biotech's Third Quarter 2024 Results and Clinical Strategy Update Conference Call. |
seekingalpha.com |
2024-11-14 13:18:51 |
Czytaj oryginał (ang.) |
| EMV Capital highlights progress update from portfolio company PDS Biotech |
EMV Capital (AIM:EMVC) has noted the clinical progress update from portfolio company PDS Biotechnology alongside its third-quarter update. Frank Bedu-Addo, PDS chief executive, said: "Since our last update in August, we have been actively engaged with investors and clinicians to discuss our strategy and funding requirements for our VERSATILE-003 Phase 3 trial of Versamune® HPV + pembrolizumab compared to pembrolizumab as a potential treatment for first-line recurrent/metastatic HPV16-positive head and neck squamous cell cancer (HNSCC). |
proactiveinvestors.co.uk |
2024-11-14 13:03:31 |
Czytaj oryginał (ang.) |
| PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time |
PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will host a conference call to report financial results for the quarter ended September 30, 2024, and provide a clinical program update on Thursday, November 14, 2024, at 8:30 a.m. Eastern Time. |
globenewswire.com |
2024-11-06 10:00:00 |
Czytaj oryginał (ang.) |
| PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know |
PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-10-22 17:06:28 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for October 15th |
ORLA, BABA and PDSB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 15, 2024. |
zacks.com |
2024-10-15 15:00:24 |
Czytaj oryginał (ang.) |
| PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation |
100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully treated with Versamune ® HPV combined with chemoradiation (N=8) 88% (15/17) of patients had a complete metabolic response IMMUNOCERV Phase 2 clinical trial results presented at ASTRO Annual Meeting 2024 |
globenewswire.com |
2024-10-02 12:00:00 |
Czytaj oryginał (ang.) |
| PDS Biotechnology: Continuing The Holding Pattern |
PDS Biotechnology is focusing on an HPV-directed immunotherapy as its main near-term hope, with new data presented at the ESMO Congress. Strengths include promising clinical data and a focused pipeline, while risks involve typical biotech uncertainties and financial sustainability. The bottom-line summary suggests a cautious yet optimistic outlook, emphasizing the importance of upcoming clinical milestones and financial health. |
seekingalpha.com |
2024-09-23 14:39:38 |
Czytaj oryginał (ang.) |
| PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024 |
PRINCETON, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, will present updated data from the VERSATILE-002 trial evaluating first-line treatment with Versamune® HPV (formerly PDS0101) in combination with KEYTRUDA® (pembrolizumab) in patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) during a poster presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2024 on September 14, 2024, in Barcelona, Spain. |
globenewswire.com |
2024-09-09 12:00:00 |
Czytaj oryginał (ang.) |
| PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference |
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York City. |
globenewswire.com |
2024-09-03 12:00:00 |
Czytaj oryginał (ang.) |
| PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024 |
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will report financial results for the second quarter of 2024 and provide a business update on Tuesday, August 13, 2024, before the market opens. The press release will be available in the Investor Relations section of the Company's website at www.pdsbiotech.com. |
globenewswire.com |
2024-08-07 12:00:00 |
Czytaj oryginał (ang.) |
| PDS Biotechnology Corporation (PDSB) Clinical Program Update Conference Call (Transcript) |
PDS Biotechnology Corporation (NASDAQ:PDSB ) Clinical Program Update Conference Call August 1, 2024 8:00 AM ET Company Participants Mike Moyer - LifeSci Advisors Frank Bedu-Addo - Chief Executive Officer Kirk Shepard - Chief Medical Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Mayank Mamtani - B. Riley Securities Joseph Pantginis - H. |
seekingalpha.com |
2024-08-02 13:12:05 |
Czytaj oryginał (ang.) |
| PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer |
Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J. |
globenewswire.com |
2024-08-01 11:45:00 |
Czytaj oryginał (ang.) |
| PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time |
PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will host a conference call to provide a clinical program update on Thursday, August 1, 2024, at 8:00 a.m. ET. |
globenewswire.com |
2024-07-31 20:01:00 |
Czytaj oryginał (ang.) |
| PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results |
Provided Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer |
globenewswire.com |
2024-05-15 12:00:00 |
Czytaj oryginał (ang.) |
| PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer |
30 month median overall survival (OS); median OS independent of patient CPS score ORR 34% (CPS≥1); 48% (CPS≥20) Phase 3 registrational trial planned to initiate in 2024 PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, hosted a Key Opinion Leader event on May 8, 2024 during which prominent experts in head and neck squamous cell cancer (“HNSCC”) discussed positive, updated VERSATILE-002 data and the unmet need in HPV16-positive HNSCC. |
globenewswire.com |
2024-05-09 21:46:00 |
Czytaj oryginał (ang.) |
| PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024 |
PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will report financial results for the first quarter of 2024 and provide a business update on Wednesday, May 15, 2024, before the market opens. The press release will be available in the Investor Relations section of the Company's website at www.pdsbiotech.com. |
globenewswire.com |
2024-05-07 12:00:00 |
Czytaj oryginał (ang.) |
| PDS Biotechnology Announces Details of Virtual KOL Event |
Virtual Webinar Updated VERSATILE-002 Phase 2 Trial Results, Unmet Treatment Needs in Advanced Head and Neck Cancer and Planned Triple Combination Trial to be held May 8, 2024 Virtual Webinar Updated VERSATILE-002 Phase 2 Trial Results, Unmet Treatment Needs in Advanced Head and Neck Cancer and Planned Triple Combination Trial to be held May 8, 2024 |
globenewswire.com |
2024-05-03 12:00:00 |
Czytaj oryginał (ang.) |